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Available online 14 January 2016The KCL025 human embryonic stem cell line was derived from an embryo donated for research that carried an
autosomal dominant mutation in the NF1 gene encoding neuroﬁbromin (c.3739–3742 ΔTTTG). Mutations in
this gene have been linked to neuroﬁbromatosis type 1, juvenile myelomonocytic leukemia and Watson syn-
drome. The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts.
Both the derivation and cell line propagation were performed in an animal product-free environment. Pluripo-
tent state and differentiation potential were conﬁrmed by in vitro assays.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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in vitro.Materials and methods
Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in the meantime new versions of PIS/consent are
implemented, we do not send these to the patients or ask them to
re-sign; the whole process is done with the version that was given
them initially. The PIS/consent documents (PGD-V.8) were created on
Jul. 01, 2010. HFEA Code of Practice that was in effect at the time of
document creation: Edition 8–R.2 (http://www.hfea.gov.uk/2999.
html). The donor couple signed the consent on Oct. 28, 2010. HFEA
Code of Practice thatwas in effect at the time of donor signature: Edition
8–R.2. HFEA Code of Practice Edition 8–R.2 was in effect 07 Apr.
2010–Apr. 06, 2011.Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFFs).Cell culture
ICM plated onmitotically inactivated HFF was cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed
mechanically from outgrowth (Ilic et al., 2007, 2010). hESC colonies
were expanded and cryopreserved at the third passage.4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
onies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.
Fig. 3. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm andα-
fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 100 μm.
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Straws with the earliest frozen passage (p.2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cells were part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012; Petrova et al.,
2014).Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro as described (Ilic et al., 2012; Stephenson et al., 2012; Petrova
et al., 2014).HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA)
hybridization protocol at the certiﬁed Clinical Transplantation Laborato-
ry, Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al., 2013).Author disclosure statement
There are no competing ﬁnancial interests in this study.
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